Experts recommend categorising Obesity into two types
New criteria agreed for diagnosis and treatment of two types of obesity – Clinical and Pre-Clinical
Experts from across the world have launched new classification of obesity into two types.
The work has been led by the Lancet Commission involving 58 doctors, patients and experts worldwide, who joined up with the aim of achieving a consensus for better understanding, diagnosis and treatment of obesity.
The commission has recommended that obesity be differentiated into two categories: 1) Clinical Obesity – when organs and functions in the body are not working properly due to excess body fat and 2) Pre-clinical Obesity when organs are functioning, but are at risk due to excess body fat.
The Commission is presenting its findings at an international event in London today (16/01/25), and recommends no longer using Body Mass Index (BMI) alone to diagnose obesity, as this can lead to under-diagnosis and over-diagnosis of obesity.
Regarding Clinical Obesity the Commission said:
‘People with Clinical Obesity have reduced organ function (such as breathlessness or heart failure) and / or have substantial trouble with movement and day-to-day activities such as bathing, dressing, eating and continence – due to excess body fat.’
Regarding Pre-clinical Obesity the Commission said:
‘People living with Pre-clinical Obesity have excess body fat but do not have reduced organ function and can complete day-to-day activities unhindered. However, they do have increased risk of developing clinical obesity and other diseases such as type 2 diabetes, cardiovascular disease and some cancers.’
The Commission recommended that all people living with obesity receive health advice and evidence-based care when needed – free of stigma and blame – with different treatment strategies applied by doctors depending on the category of obesity.
‘Treatment for clinical obesity should be aimed at fully regaining or improving the body functions reduced by excess body fat. The type of treatment and management – whether lifestyle, medication or surgery – should be informed by risk, benefit assessment and discussion with the patient. Successful treatment should be measured by the improvement of signs and symptoms, rather than weight loss alone.’
‘For people living with pre-clinical obesity, the approach to their care should target risk-reduction. This may require health counselling or active treatment may be necessary.’
President of Irish Society for Clinical Nutrition and Metabolism (IrSPEN) and member of the Lancet Commission Professor Carel le Roux said that the differentiation between pre-clinical and clinical obesity would also help policy and investment planning and decisions in public health services.
“Policy makers should ensure adequate and equitable access to evidence-based treatments for individuals with clinical obesity and pre-clinical obesity as appropriate.”
European Coalition of People living with Obesity representative Vicky Mooney, who was one of the Commissioners and representing patients’ perspectives, highlighted the importance of tackling stigma: “Weight based bias and stigma are major obstacles in efforts to effectively manage clinical obesity and pre-clinical obesity. Healthcare professionals and policy makers should receive proper training to address this.”
Royal College of Surgeons Head of the School of Population Health Professor Edward Gregg, another member of the Commission, added that it was also important that public understanding of the disease and its two categories is raised.
Professor le Roux concluded that this consensus of world experts achieves a level playing field to allow all stakeholders to have an agreed language and understanding. “We can now start a serious conversation about how we can work together and move away from the idea of weight loss to the idea of health gain to address both clinical obesity and preclinical obesity.”
An estimated 1.25 million people in Ireland, 24% of the population, are living with obesity.
Further Information
Ronan Cavanagh, Cavanagh Communications: (086) 317 9731.
A link to the Lancet Commission publication is here:
https://www.thelancet.com/commissions/clinical-obesity
About IrSPEN
The Irish Society for Clinical Nutrition and Metabolism (IrSPEN) is a multi-disciplinary professional organisation dedicated to optimising screening for and management of those at risk of malnutrition or other nutritional problems in Ireland, whether in hospital or in the community. www.irspen.ie
Conflict of Interest statements
Carel le Roux is a Director of the Irish Society for Nutrition and Metabolism. He reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards and speakers panels of Novo Nordisk, Roche, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Gila, Irish Life Health, Boehringer Ingelheim, Currax, Zealand Pharma, Keyron, AstraZeneca, and Rhythm Pharma. He also provides obesity clinical care in the My Best Weight clinic and Beyond BMI clinic and is a shareholder in these clinics.



